Global Pneumococcal Vaccine Market Projected to Grow at 8.3% CAGR through 2026
The
global pneumococcal vaccine market is projected to grow at a CAGR of 8.3%
during the assessment period 2017-2026, according to a latest research report
added to the vast database of Market Research Reports Search Engine (MRRSE).
According to the report titled “Pneumococcal
Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and
Forecast 2017 – 2026”, rising consumer awareness and favorable
government policies are promoting the growth of the global market.
According
to the report, concerted efforts by both government and private sector to curb
the threat of pneumoniae has led to increased demand for pneumococcal vaccines.
Governments in developed countries have made pneumococcal vaccines a standard
in their healthcare offerings, whereas public-private partnership in developing
countries is fostering sales of pneumococcal vaccines in developing countries.
However, the high cost of these vaccines continue to challenge adoption,
especially in cost-intensive markets. Further, there is limited awareness among
parents in developing countries about the importance of pneumococcal vaccines.
In
addition to offering detailed analysis on the key drivers, restraints, opportunities,
and threats influencing market growth, the report also offers lucid
segment-wise insights to give readers a holistic perspective on market
scenario. The market has been analyzed on the basis of product type,
distribution channel, and region. By product type, the key segments include
7-Valent, 23-Valent, 13-Valent, and 10-Valent. The key distribution channels
analyzed in the report include hospitals, clinics, and others. The region-wise
analysis includes North America, Latin America, Europe, Japan, Asia Pacific
excluding Japan (APEJ), and Middle East & Africa (MEA).
According
to the report, 13-Valent pneumococcal vaccines are likely to remain the largest
product segment. By the end of forecast period, the demand for 13-Valent
pneumococcal vaccines is likely to reach a valuation of US$ 9.5 Bn. This
product type also includes 19A and 6A serotypes, which have promoted their
growth among end-users. By distribution channel, hospitals are likely to remain
the largest segment, and are projected to rake in nearly US$ 12.4 Bn worth of
revenues by the end of forecast period.
North
America continues to be the largest market for pneumococcal vaccines globally.
The demand for pneumococcal vaccines in North America is concentrated in the
US. Western Europe and APEJ are the other key markets for pneumococcal vaccines
globally. The report also includes a competitive landscape that profiles the
strategies of some of the leading players in the market. Some of the key
players include Merck & Co. Inc., Sanofi, Pfizer, Inc., and GlaxoSmithKline
PLC.
To Know More About This Report Visit the given Link - https://www.mrrse.com/pneumococcal-vaccines-market
Comments
Post a Comment